Document is current
Any future updates will be listed below
-
Authors
Xie, Qianqian
Chen, Ziwei
Wang, Jiafeng
Zhang, Huisi
Wang, Yan
Wang, Xiaoyu
Li, Chunyan
Wang, Yongxiang
Cong, Lin
Ferreira, Daniel
Welmer, Anna-Karin
Song, Lin
Du, Yifeng
Qiu, Chengxuan
-
Funding
Funding for this research was provided by:
the Swedish Research Council (2022-00916, 2017-05819 and 2020-01574)
the Center for Innovative Medicine (20200505 and FoUI-988826)
the regional agreement on medical training and clinical research of Stockholm Region (FoUI-962240 and FoUI-987534)
the Swedish Brain Foundation (FO2023-0261, FO2022-0175, and FO2021-0131)
the Swedish Alzheimer Foundation (AF-968032, AF-980580, and AF-994058)
the Nature Science Foundation of Shandong Province (ZR2020QH098)
the National Key R&D Program of China (2017YFC1310100)
the STI2030-Major Project (2021ZD0201808 and 2022ZD0211600)
the National Nature Science Foundation of China (82171175, 82011530139, and 82001120)
the Academic Promotion Program of Shandong First Medical University (2019QL020 and 2020RC009)
the Taishan Scholar Program of Shandong Province (ts20190977 and Tsqn201909182)
Integrated Traditional Chinese and Western Medicine Program in Shandong Province (YXH2019ZXY008)
the Swedish Foundation for International Cooperation in Research and Higher Education (CH2019-8320)
- License Information
-
More Information
Article History
Received: 8 December 2024
Accepted: 14 March 2025
First Online: 3 April 2025
Declarations
:
: The MIND-China protocol was approved by the Ethics Committee at Shandong Provincial Hospital Affiliated to Shandong First Medical University in Jinan. Written informed consent was obtained from all the participants or from a proxy (a guardian or a family member) if participants were not able to give the consent. The MIND-China study was registered in the Chinese Clinical Trial Registry (registration No.: ChiCTR1800017758).
: All authors gave their consent for publication.
: The authors declare no competing interests.
